Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin-Reference-Cited by-同舟云学术

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin

Published:2017-11-25 Issue:1 Volume:36 Page:e12308
ISSN:1755-5914
Container-title:Cardiovascular Therapeutics
language:en
Short-container-title:Cardiovasc Ther

Author:

Fazio Sergio¹,Robertson David G.²,Joh Tenshang³,Wan Hong³,Riel Tom³,Forgues Philippe³,Baum Charles M.⁴,Garzone Pamela D.³,Gumbiner Barry³^ORCID

Affiliation:

1. The Knight Cardiovascular Institute; Oregon Health and Science University; Portland OR USA

2. Atlanta Diabetes Associates; Atlanta GA USA

3. Pfizer Inc.; South San Francisco and San Diego CA USA

4. Mirati Therapeutics Inc.; San Diego CA USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1755-5922.12308/fullpdf

Reference34 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

2. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study;Bruckert;Cardiovasc Drugs Ther,2005

3. Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys;Tattersall;PLoS One,2013

4. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated;Leren;PLoS One,2011

5. PCSK9: a convertase that coordinates LDL catabolism;Horton;J Lipid Res,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

2. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology;Cancers;2023-02-22

3. Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats;International Journal of Toxicology;2022-06-07

4. Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia;Journal of Personalized Medicine;2021-08-31

5. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia;Endocrinology and Metabolism;2021-04-30